Drug transporters in breast cancer: response to anthracyclines and taxanes

Iben Kümler; Jan Stenvang; José Moreira; Nils Brünner; Dorte Lisbet Nielsen

doi:10.1586/14737140.2015.1067610

Drug transporters in breast cancer: response to anthracyclines and taxanes

Iben Kümler, Jan Stenvang, José Moreira, Nils Brünner, Dorte Lisbet Nielsen

Department of Clinical Medicine

4 Citations (Scopus)

Abstract

Despite the advances that have taken place in the past decade, including the development of novel molecular targeted agents, cytotoxic chemotherapy remains the mainstay of cancer treatment. In breast cancer, anthracyclines and taxanes are the two main chemotherapeutic options used on a routine basis. Although effective, their usefulness is limited by the inevitable development of resistance, a lack of response to drug-induced cancer cell death. A large body of research has resulted in the characterization of a plethora of mechanisms involved in resistance; ATP-binding cassette transporter proteins, through their function in xenobiotic clearance, play an important role in resistance. We review here the current evidence for drug transporters as biomarkers and the benefit of adding drug transporter modulators to conventional chemotherapy.

Original language	English
Journal	Expert Review of Anticancer Therapy
Volume	15
Issue number	9
Pages (from-to)	1075-1092
Number of pages	18
ISSN	1473-7140
DOIs	https://doi.org/10.1586/14737140.2015.1067610
Publication status	Published - 2 Sept 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.2015.1067610

Cite this

@article{a1265c0696284ddfa7f532f6d2421e9f,

title = "Drug transporters in breast cancer: response to anthracyclines and taxanes",

abstract = "Despite the advances that have taken place in the past decade, including the development of novel molecular targeted agents, cytotoxic chemotherapy remains the mainstay of cancer treatment. In breast cancer, anthracyclines and taxanes are the two main chemotherapeutic options used on a routine basis. Although effective, their usefulness is limited by the inevitable development of resistance, a lack of response to drug-induced cancer cell death. A large body of research has resulted in the characterization of a plethora of mechanisms involved in resistance; ATP-binding cassette transporter proteins, through their function in xenobiotic clearance, play an important role in resistance. We review here the current evidence for drug transporters as biomarkers and the benefit of adding drug transporter modulators to conventional chemotherapy.",

author = "Iben K{\"u}mler and Jan Stenvang and Jos{\'e} Moreira and Nils Br{\"u}nner and Nielsen, {Dorte Lisbet}",

year = "2015",

month = sep,

day = "2",

doi = "10.1586/14737140.2015.1067610",

language = "English",

volume = "15",

pages = "1075--1092",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor & Francis",

number = "9",

}

TY - JOUR

T1 - Drug transporters in breast cancer

T2 - response to anthracyclines and taxanes

AU - Kümler, Iben

AU - Stenvang, Jan

AU - Moreira, José

AU - Brünner, Nils

AU - Nielsen, Dorte Lisbet

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Despite the advances that have taken place in the past decade, including the development of novel molecular targeted agents, cytotoxic chemotherapy remains the mainstay of cancer treatment. In breast cancer, anthracyclines and taxanes are the two main chemotherapeutic options used on a routine basis. Although effective, their usefulness is limited by the inevitable development of resistance, a lack of response to drug-induced cancer cell death. A large body of research has resulted in the characterization of a plethora of mechanisms involved in resistance; ATP-binding cassette transporter proteins, through their function in xenobiotic clearance, play an important role in resistance. We review here the current evidence for drug transporters as biomarkers and the benefit of adding drug transporter modulators to conventional chemotherapy.

AB - Despite the advances that have taken place in the past decade, including the development of novel molecular targeted agents, cytotoxic chemotherapy remains the mainstay of cancer treatment. In breast cancer, anthracyclines and taxanes are the two main chemotherapeutic options used on a routine basis. Although effective, their usefulness is limited by the inevitable development of resistance, a lack of response to drug-induced cancer cell death. A large body of research has resulted in the characterization of a plethora of mechanisms involved in resistance; ATP-binding cassette transporter proteins, through their function in xenobiotic clearance, play an important role in resistance. We review here the current evidence for drug transporters as biomarkers and the benefit of adding drug transporter modulators to conventional chemotherapy.

U2 - 10.1586/14737140.2015.1067610

DO - 10.1586/14737140.2015.1067610

M3 - Journal article

C2 - 26313418

SN - 1473-7140

VL - 15

SP - 1075

EP - 1092

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 9

ER -

Drug transporters in breast cancer: response to anthracyclines and taxanes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this